In recent years, the treatment and diagnosis of childhood cancer has led to
dramatic improvements in survival rates. Approximately, 75-80% of affected children
survived a malignant disease. However, the improvement in prognosis has been
achieved at the expense of serious late effects from cancer and cancer treatment.
Endocrinological late effects are the most common problem and were found in
approximately 20-30% of child cancer survivors (CCSs). Endocrinologists should
participate in the follow-up of CCSs in collaboration with pediatric oncologists.
Further, long-term follow up is necessary for CCSs because treatment-related
complications may occur during childhood and many years after therapy.
Keywords: Child cancer survivors, Growth impairment, Late effect, Malignant
disease, Treatment.
